ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Lung Neoplasms
- Registration Number
- NCT00051506
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy.
- Have received no prior chemotherapy for your disease.
- Have at least one measurable lesion.
- have an adequate performance status.
- Sign an informed consent form.
Exclusion Criteria
- Have previously received chemotherapy for your lung cancer.
- Have been treated with a investigational drug within the last 30 days. Have previously completed or withdrawn from this study or any other study investigating ALIMTA.
- Have received radiation therapy within the last 1-2 weeks.
- Have brain metastasis that is uncontrolled.
- Have active infection or other serious condition.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
🇺🇸Charleston, South Carolina, United States